Vitruvias Therapeutics Recalls Thyroid Tablets Due to Superpotency, FDA Announces
Vitruvias Therapeutics Inc. has issued a voluntary recall of nearly 2,000 bottles of Thyroid Tablets, USP, after the product was found to be superpotent, meaning the tablets contain more active ingredient than labeled. The U.S. Food & Drug Administration (FDA) announced the recall, which affects a single lot of the medication. The company stated it is notifying wholesalers to halt distribution and is arranging for the destruction of any remaining recalled inventory. This recall is particularly concerning because thyroid medicine is intended to replace hormones that the body does not produce in sufficient amounts, and excessive hormone levels can lead to serious health complications.
The key issue is the potential for the recalled tablets to contain more thyroid hormone than intended. For patients relying on thyroid hormone replacement therapy, taking a superpotent dose could result in symptoms of hyperthyroidism, such as rapid heart rate, anxiety, weight loss, and in severe cases, cardiac issues. The FDA emphasizes that the correct response to a recall can depend on why the medicine was prescribed and the patient’s individual treatment needs. Patients are advised to consult their healthcare provider before making any changes to their medication regimen.
This recall follows a separate thyroid medication recall earlier this year involving Major Pharmaceuticals, which initiated a voluntary recall of its levothyroxine sodium tablets in July after the FDA found those pills were subpotent. Subpotent medications contain less active ingredient than labeled, which can also be dangerous for patients who depend on precise dosing. Together, these incidents highlight ongoing concerns about quality control in the manufacturing of thyroid medications.
Vitruvias Therapeutics is cooperating with the FDA to ensure the recall is executed effectively. Patients who have the recalled product should not use it and should return it to the place of purchase or contact the company for instructions. The FDA encourages healthcare professionals and patients to report any adverse events or quality issues related to the recalled product through the MedWatch program. As always, patients should remain vigilant and consult their healthcare provider with any questions or concerns about their thyroid medication.
Shimanta Das 
